Experimental Alzheimer’s Drug Shows Benefits in Phase 3 Trial, Company Says

September 28, 2022

(NBC News) – The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results were announced in a news release and have not yet been peer-reviewed.  (Read More)